Suso Platero

1.8k total citations
22 papers, 1.1k citations indexed

About

Suso Platero is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Suso Platero has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Suso Platero's work include Fibroblast Growth Factor Research (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Genomics and Diagnostics (5 papers). Suso Platero is often cited by papers focused on Fibroblast Growth Factor Research (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Genomics and Diagnostics (5 papers). Suso Platero collaborates with scholars based in United States, Belgium and Spain. Suso Platero's co-authors include Craig Fairchild, Tai W. Wong, Karen A. Reeves, Edwin Clark, Peter Shaw, Fei Huang, Francis Lee, Xia Han, Josep Tabernero and Feng Luo and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Suso Platero

22 papers receiving 1.1k citations

Peers

Countries citing papers authored by Suso Platero

Since Specialization

Citations

This map shows the geographic impact of Suso Platero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suso Platero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suso Platero more than expected).

Fields of papers citing papers by Suso Platero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suso Platero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suso Platero. The network helps show where Suso Platero may publish in the future.

Co-authorship network of co-authors of Suso Platero

This figure shows the co-authorship network connecting the top 25 collaborators of Suso Platero. A scholar is included among the top collaborators of Suso Platero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suso Platero. Suso Platero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fast-tracking drug development with biomarkers and companion diagnostics 2024 ·Journal of Cancer Metastasis and Treatment ·(unknown), (unknown), Suso Platero	3
2	Immuno-oncology trends: preclinical models, biomarkers, and clinical development 2022 ·Journal for ImmunoTherapy of Cancer ·(unknown), Suso Platero, Kamal S. Saini, Giuseppe Curigliano, Steven M. Anderson	38
3	Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients 2019 ·Nature Communications ·Xu‐Chao Zhang, Jun Wang, Guoguang Shao, Qun Wang, Xiaotao Qu, Bo Wang, Christopher Moy, Yue Fan, Zayed Albertyn, Xiayu Huang, Jingyu Zhang, Yang Qiu, Suso Platero, Matthew V. Lorenzi, Enrique Zudaire, Jennifer Yang, Ying Cheng, Lin Xu, Yi‐Long Wu	145
4	Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions 2019 ·Nature Communications ·Jennifer Beane, Sarah A. Mazzilli, Joshua D. Campbell, Grant Duclos, Kostyantyn Krysan, Christopher Moy, Catalina Perdomo, Michael Schäffer, Gang Liu, Sherry Zhang, Hanqiao Liu, Jessica Vick, Samjot S. Dhillon, Suso Platero, Steven M. Dubinett, Christopher S. Stevenson, Mary E. Reid, Marc E. Lenburg, Avrum Spira	57
5	Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib 2017 ·Molecular Cancer Therapeutics ·Jayaprakash D. Karkera, (unknown), (unknown), Dana Gaffney, (unknown), Ademi Santiago-Walker, Christopher Moy, Peter King, Michael Sharp, Rastislav Bahleda, Feng Luo, John Alvarez, Matthew V. Lorenzi, Suso Platero	43
6	Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression 2017 ·Clinical Cancer Research ·Jennifer Beane, Sarah A. Mazzilli, Anna M. Tassinari, Gang Liu, (unknown), Hanqiao Liu, (unknown), Samjot S. Dhillon, Suso Platero, Marc E. Lenburg, Mary E. Reid, Stephen Lam, Avrum Spira	30
7	The Case for a Pre-Cancer Genome Atlas (PCGA) 2016 ·Cancer Prevention Research ·Joshua D. Campbell, Sarah A. Mazzilli, Mary E. Reid, Samjot S. Dhillon, Suso Platero, Jennifer Beane, Avrum Spira	66
8	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors 2015 ·Journal of Clinical Oncology ·Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, Jeffrey R. Infante, Alain C. Mita, Antoîne Italiano, Emiliano Calvo, Víctor Moreno, Bárbara Adamo, Anas Gazzah, Bob Zhong, Suso Platero, Johan W. Smit, Kim Stuyckens, Moitreyee Chatterjee‐Kishore, Jordi Rodón, Vijay Peddareddigari, Feng Luo, Jean‐Charles Soria	299
9	Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors 2014 ·Cancer Research ·Rodrigo Dienstmann, Rastilav Bahleda, Bárbara Adamo, Jordi Rodón, Andréa Varga, Anas Gazzah, Suso Platero, (unknown), Timothy Perera, Bob Zhong, Kim Stuyckens, Yusri Elsayed, Chris H. Takimoto, Vijay Peddareddigari, Josep Tabernero, Feng Luo, Jean‐Charles Soria	21
10	Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. 2014 ·Journal of Clinical Oncology ·Rastislav Bahleda, Rodrigo Dienstmann, Bárbara Adamo, Anas Gazzah, Jeffrey R. Infante, Bob Zhong, Suso Platero, (unknown), Timothy Perera, Kim Stuyckens, (unknown), Vijay Peddareddigari, Jean‐Charles Soria, Feng Luo, Josep Tabernero	34
11	Abstract 1738: JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy 2014 ·Cancer Research ·Timothy Perera, (unknown), Jorge Vialard, Tinne Verhulst, N. Esser, Berthold Wroblowski, Ron Gilissen, Eddy Freyne, Peter King, Suso Platero, Olivier Querolle, Laurence Mévellec, Christopher W. Murray, Lynsey Fazal, Gordon Saxty, George A. Ward, Matthew Squires, Neil T. Thompson, David R. Newell, Patrick Angibaud	8
12	Abstract 2408: Identification of R-Spondin fusions in various types of human cancer 2014 ·Cancer Research ·(unknown), (unknown), (unknown), Dana Gaffney, Christopher Moy, Suso Platero, Matthew V. Lorenzi, Jayaprakash D. Karkera	4
13	Abstract 5: Identification of androgen receptor (AR) splice variants, AR somatic mutations and TMPRSS2:ETS fusion genes in prostate cancer FFPET by qRT-PCR. 2013 ·Cancer Research ·Dana Gaffney, Gabriela Martinez, (unknown), Suso Platero, Deborah Ricci, Jayaprakash D. Karkera	1
14	Abstract P5-01-09: Identification of Molecular Apocrine Triple Negative Breast Cancer Using a Novel 2-Gene Assay and Comparison with Androgen Receptor Protein Expression and Gene Expression Profiling by DASL 2012 ·Cancer Research ·J. Álvarez, Michael Schäffer, Jayaprakash D. Karkera, G Martı́nez, Dana Gaffney, (unknown), (unknown), (unknown), (unknown), Deborah Ricci, Suso Platero	2
15	A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, José A. López-Martín, Jaume Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett M. Hall, Zhilong Yuan, Roland E. Knoblauch, Sen Hong Zhuang	46
16	Conference Scene: Diagnostics and Personalized Medicine: Observations from the World Companion Diagnostics Summit 2011 ·Pharmacogenomics ·Mark Curran, Suso Platero	3
17	Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases 2008 ·Journal of Clinical Oncology ·Suso Platero, (unknown), Gordon C. Jayson, Derek J. Jonker, Lee S. Rosen, (unknown), John E. Kelsey, David Feltquate, (unknown), Susan Galbraith	4
18	Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection 2007 ·Cancer Research ·Fei Huang, Karen A. Reeves, Xia Han, Craig Fairchild, Suso Platero, Tai W. Wong, Francis Lee, Peter Shaw, Edwin Clark	274
19	Preclinical discovery and clinical validation of predictive markers of response to cetuximab (Erbitux™) in metastatic colorectal cancer 2006 ·Cancer Research ·(unknown), (unknown), Xin Huang, Tai W. Wong, Suso Platero, Christiane Langer, (unknown), Lynn Ploughman, Edwin Clark, David J. Mauro	3
20	Identification of pharmacogenomic markers for predicting sensitivity to BMS-354825, a SRC/ABL kinase inhibitor 2005 ·Journal of Clinical Oncology ·Edwin Clark, Karen A. Reeves, Xiaojun Han, (unknown), Craig Fairchild, (unknown), Suso Platero, Tai W. Wong, (unknown), Fei Huang	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact